Focused On-demand Library for Period circadian protein homolog 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P56645

UPID:

PER3_HUMAN

Alternative names:

Cell growth-inhibiting gene 13 protein; Circadian clock protein PERIOD 3

Alternative UPACC:

P56645; Q5H8X4; Q5H8X5; Q969K6; Q96S77; Q96S78; Q9C0J3; Q9NSP9; Q9UGU8

Background:

Period circadian protein homolog 3, also known as Cell growth-inhibiting gene 13 protein, plays a pivotal role in the circadian clock. This internal time-keeping system regulates physiological processes through 24-hour rhythms in gene expression, influencing metabolism, sleep, and other vital functions. The protein is part of a transcription/translation feedback loop crucial for maintaining circadian rhythms, with implications for cardiovascular health, cancer, metabolic syndromes, and aging.

Therapeutic significance:

Linked to Advanced sleep phase syndrome, familial, 3, Period circadian protein homolog 3's understanding could pave the way for innovative treatments targeting sleep disorders and circadian rhythm disruptions.